Saltar al contenido
Merck

Invasive breast carcinoma: influence of prognosis and patient-related factors on kinetic MR imaging characteristics.

Radiology (2013-09-14)
Ingrid Millet, Fernanda Curros-Doyon, Nicolas Molinari, Emmanuelle Bouic-Pages, Xavier Prat, Chakib Alili, Patrice Taourel
RESUMEN

To retrospectively compare the kinetic magnetic resonance (MR) imaging characteristics of invasive breast carcinomas with both prognostic tumoral and patient-related parameters. This HIPAA-compliant retrospective study was approved by the institutional review board, and informed consent was waived. From January 2008 to January 2011, 273 consecutive women (mean age, 55 years; range, 23-83 years) with invasive breast cancers who had undergone MR imaging were selected. The kinetic curves were retrospectively classified according to the Breast Imaging Reporting and Data System lexicon. Initial enhancement and maximal enhancement percentages, time to peak enhancement, and the signal enhancement ratio were calculated for each lesion. Kinetic characteristics were compared according to tumoral parameters (size, pathologic type, grade, hormone receptor status, and c-erbB-2 status) and patient parameters (menopausal status, personal history of breast carcinoma) by means of univariate and then multivariate analysis by using false-discovery-rate statistics. Lesions in menopausal patients exhibited less suspicious quantitative and qualitative characteristics than lesions in nonmenopausal patients. There was an independent association between the kinetic characteristics and menopausal status, with an odds ratio of 2.94 for the lack of rapid initial contrast material uptake and of 2.38 for the lack of washout in menopausal patients as compared with nonmenopausal patients. The odds ratio was 4.00 for not having rapid initial contrast material uptake in patients with a personal history of ipsilateral breast cancer. Kinetic data in invasive breast cancer are associated with the patient's menopausal status, with a typical kinetic pattern of malignancy being less common in menopausal patients.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
N- Metil-D-glucamina, 99.0-100.5% (titration)
Sigma-Aldrich
N- Metil-D-glucamina, ReagentPlus®, ≥99.0% (T)
Sigma-Aldrich
N- Metil-D-glucamina, 99.0-100.5% dry basis, meets USP testing specifications